Insilico's rentosertib enters Phase III trial
Insilico Medicine's AI-designed IPF drug candidate, rentosertib, has reportedly entered Phase III after early lung and aging-clock signals. The reports appeared between 7 and 10 September 2026.
Who is affected and how
- pharmaceuticals
- This is the first major test of whether an AI-discovered molecule can also succeed in the pivotal phase.
- doctor
- For pulmonologists, Phase III will provide the real efficacy and safety data.
Sources
- Particle: AI-Designed Drug Rentosertib Enters Phase III After Early Lung and Aging-Clock Signalsparticle.news · Sep 7, 2026
- Insilico Medicine’s AI drug enters Phase III dosing. Can rentosertibbusiness-news-today.com · Sep 10, 2026
- Insilico’s rentosertib becomes first AI-discovered drug to enter Phase IIIallsci · Sep 10, 2026
- Insilico Medicine starts Phase III trial for AI... | Pluangpluang.com · Sep 9, 2026
- Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World’s First Phase III Trial of a Generative AI-Driven Innovative Druginsilico medicine · Sep 10, 2026
- First Generative AI-Discovered Drug Advances to Phase III Human Studies - Pharmacallypharmacally.com · Sep 11, 2026
- Insilico Medicine's new AI-based drug has entered phase III trialstheintelligent.hu · Sep 10, 2026 · magyar
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.